اخبار و اعلانات

 آمار

تعداد نشریات282
تعداد نشریات سازمان80
تعداد شماره‌ها3,251
تعداد مقالات35,917
تعداد مشاهده مقاله54,572,227
تعداد دریافت فایل اصل مقاله93,694,243
Suvvari, T., P, C, Kuppili, S, Kandi, V, Kutikuppala, L. V. S, Kandula, V. D. K, Mishra, S, Sarangi, A. K, Mohapatra, R. K, Dhama, K. (1400). Consecutive Hits of COVID-19 in India: The Mystery of Plummeting Cases and Current Scenario. سامانه مدیریت نشریات علمی, 76(5), 1165-1174. doi: 10.22092/ari.2021.356147.1791
T. K Suvvari; C P; S Kuppili; V Kandi; L. V. S Kutikuppala; V. D. K Kandula; S Mishra; A. K Sarangi; R. K Mohapatra; K Dhama. "Consecutive Hits of COVID-19 in India: The Mystery of Plummeting Cases and Current Scenario". سامانه مدیریت نشریات علمی, 76, 5, 1400, 1165-1174. doi: 10.22092/ari.2021.356147.1791
Suvvari, T., P, C, Kuppili, S, Kandi, V, Kutikuppala, L. V. S, Kandula, V. D. K, Mishra, S, Sarangi, A. K, Mohapatra, R. K, Dhama, K. (1400). 'Consecutive Hits of COVID-19 in India: The Mystery of Plummeting Cases and Current Scenario', سامانه مدیریت نشریات علمی, 76(5), pp. 1165-1174. doi: 10.22092/ari.2021.356147.1791
Suvvari, T., P, C, Kuppili, S, Kandi, V, Kutikuppala, L. V. S, Kandula, V. D. K, Mishra, S, Sarangi, A. K, Mohapatra, R. K, Dhama, K. Consecutive Hits of COVID-19 in India: The Mystery of Plummeting Cases and Current Scenario. سامانه مدیریت نشریات علمی, 1400; 76(5): 1165-1174. doi: 10.22092/ari.2021.356147.1791

Consecutive Hits of COVID-19 in India: The Mystery of Plummeting Cases and Current Scenario

Archives of Razi Institute
مقاله 4، دوره 76، شماره 5، بهمن و اسفند 2021، صفحه 1165-1174    اصل مقاله (398.26 K)
نوع مقاله: Mini Review
شناسه دیجیتال (DOI): 10.22092/ari.2021.356147.1791
نویسندگان
T. K Suvvari1؛ C P2؛ S Kuppili3؛ V Kandi4؛ L. V. S Kutikuppala3؛ V. D. K Kandula5؛ S Mishra6؛ A. K Sarangi7؛ R. K Mohapatra* 8؛ K Dhama* 9
1NTR University of Health Sciences, Vijayawada, India
2Rungta College of Dental Sciences and Research, Bhilai, India
3Konaseema Institute of Medical Sciences and Research Foundation, Amalapuram, India
4Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, India
5GSL Medical College and General Hospital, Rajahmundry, India
6Bioenergy Lab, School of Biotechnology, KIIT Deemed University, Bhubaneswar, India
7Department of Chemistry, School of Applied Sciences, Centurion University of Technology and Management, Odisha, India
8Department of Chemistry, Government College of Engineering, Keonjhar, India
9Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, India
چکیده
The novel coronavirus disease 2019 (COVID-19)-related pandemic has been in existence for almost 2 years now after its possible emergence from a wet market in the city of Wuhan of the Chinese mainland. Evidence of the emergence and transmission of this virus was attributed to bats and pangolins. The causative virus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has rapidly spread globally, affecting humans considerably with its current death toll to be over 4.7 million out of more than 233 confirmed cases as of September 2021. The virus is constantly mutating and continuously trying to establish itself in humans by increasing its transmissibility and virulence through its numerous emerging variants. Several countries have been facing multiple waves of COVID-19 outbreaks one after the other, putting the medical and healthcare establishments under tremendous stress. Although very few drugs and vaccines have been approved for emergency use, their production capabilities need to meet the needs of a huge global population. Currently, not even a quarter of the world population is vaccinated. The situation in India has worsened during the ongoing second wave with the involvement of virus variants with a rapid and huge surge in COVID-19 cases, where the scarcity of hospital infrastructure, antiviral agents, and oxygen has led to increased deaths. Recently, increased surveillance and monitoring, strengthening of medical facilities, campaigns of awareness programs, progressive vaccination drive, and high collaborative efforts have led to limiting the surge of COVID-19 cases in India to a low level. This review outlines the global status of the pandemic with special reference to the Indian scenario.
کلیدواژه‌ها
Challenges؛ COVID-19؛ COVID-appropriate behavior؛ Fears of third wave؛ Pandemic scenario؛ SARS-CoV-2؛ Second wave
سایر فایل های مرتبط با مقاله
مراجع
  1. Gupta M, Mohanta SS, Rao A, et al. Transmission dynamics of the COVID-19 epidemic in India and modeling optimal lockdown exit strategies. Int J Infect Dis. 2021;103:579-89. 
  2. Mohapatra RK, Pintilie L, Kandi V, et al. The recent challenges of highly contagious COVID-19; causing respiratory infections: symptoms, diagnosis, transmission, possible vaccines, animal models and immunotherapy. Chem Biol Drug Des. 2020;96:1187–1208.
  3. Mohapatra RK, Mishra S, Azam M, et al. COVID-19, WHO guidelines, pedagogy, and respite. Open Med. 2021;16:491–493.
  4. Mohapatra RK, Das PK, Pintilie L, et al. Infection capability of SARS-CoV-2 on different surfaces.Egypt. J Basic Appl Sci. 2021;8(1):75-80.
  5. Mohapatra RK, Perekhoda L, Azam M, et al. Computational investigations of three main drugs and their comparison with synthesized compounds as potent inhibitors of SARS-CoV-2 main protease (Mpro): DFT, QSAR, molecular docking, and in silico toxicity analysis. J King Saud Univ Sci. 2021;33(2):101315.
  6. Mukherjee A, Anand T, Agarwal A, et al. SARS-CoV-2 re-infection: development of an epidemiological definition from India. Epidemiol Infect. 2021;149:e82. 
  7. Menon V, Kar SK, Ransing R, et al. Impending Second Wave of COVID-19 Infections: What India Needs to Do? Asia Pac J Public Health. 2021;33(4): 456-457.
  8. Szarpak L, Chirico F, Pruc M, et al. Mucormycosis-a serious threat in the COVID-19 pandemic? J Infect. 2021;83(2): 237-279.
  9. Claustre J, Larcher R, Jouve T, et al. Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy. Ann Intensive Care. 2020;10:74.
  10. Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus. 2020; 12(9):e10726.
  11. Suvvari TK, Arigapudi N, Kandi V, et al. Mucormycosis: A Killer in the Shadow of COVID-19, J Mycol Med. 2021;31(3): 101161.
  12. Garg D, Muthu V, Sehgal IS, et al. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. 2021;186(2):289-298.
13.Verma DK, Bali RK. COVID-19 and Mucormycosis of the Craniofacial skeleton: Causal, Contributory or Coincidental? J Maxillofac Oral Surg. 2021;20(2):165–166.

  1. The L. India's COVID-19 emergency. The Lancet. 2021;397(10286):1683..
  2. WHO. situation report on India: who; [cited 2021.
  3. COVID-19 Dashboard. Government of India 2021.Availablefrom: https://www.mygov.in/covid-19.
  4. Thiagarajan K. Why is India having a covid-19 surge? BMJ. 2021;373:n1124.
  5. Kumar S. Second Wave of COVID-19: Emergency Situation in India. J Travel Med. 2021;28(7).
  6. Dhama K, Patel SK, Pathak M, et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med Infect Dis. 2020; 37:101755.
  7. Arumugam VA, Thangavelu S, Fathah Z, et al. COVID-19 and the World with Co-Morbidities of Heart Disease, Hypertension and Diabetes. J Pure Appl Microbiol.2020; 14(3):1623-1638.
  8. Choudhary OP, Priyanka, Singh I, et al. Second wave of COVID-19 in India: Dissection of the causes and lessons learnt. Travel Med Infect Dis. 2021;43: 102126.
  9. Suvvari TK, Hegde S, Sreeram S, et al. The COVID-19 vaccine: A race nearing the finish line. Apollo Med. 2021;18:111-121.
  10. Kar SK, Ransing R, Arafat SMY, et al. Second wave of COVID-19 pandemic in India: Barriers to effective governmental response. EClinicalMedicine. 2021;36:100915.
  11. Ghosh A, Nundy S, Mallick TK. How India is dealing with COVID-19 pandemic. Sen Int. 2020; 1.
  12. Ranjan R, Sharma A, Verma MK. Characterization of the Second Wave of COVID-19 in India. medRxiv. 2021;121(1):85-93.
  13. Mallapaty S. India’s massive COVID surge puzzles scientists. Nature. 2021;592(7856):667-8.
  14. Sv P, Lathabhavan R, Ittamalla R. What concerns Indian general public on second wave of COVID-19? A report on social media opinions. Diabetes Metab Syndr. 2021; 15(3):829-830.
  15. 28. CDC, COVID-19 Travel Information 2021. Available from: https://wwwnc.cdc.gov/travel/destinations/traveler/none/india.
  16. Sharun K, Tiwari R, Natesan SK, et al. International travel during the COVID-19 pandemic: implications and risks associated with 'travel bubbles'. J Travel Med. 2020; 27(8).
  17. Mohapatra RK, Das PK, Kandi V. Challenges in controlling COVID-19 in migrants in Odisha. India. Diabetes Metab Syndr. 2020; 14:1593-1594.
31.Samarasekera U. India grapples with second wave of COVID-19. Lancet Microbe. 2021;2(6):e238.

32.Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, Lorson CL, Byrareddy SN, Singh K. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. J Autoimmun. 2021; 124: 102715.

  1. Mishra S, Mindermann S, Sharma M, Whittaker C, Mellan TA, Wilton T, et al. Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. EClinicalMedicine. 2021;39:101064.
  2. Khan MA, Ullah S, Kumar S. A robust study on 2019-nCOV outbreaks through non-singular derivative. Eur Phys J Plus. 2021;136(2):168.
  3. Kandi V. SARS-CoV-2 Genetic Variations, Immunity, and Efficacy of Vaccines: The Current Perspectives and Future Implications. Am J Infect Dis.2021;9(3):90-97.
  4. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184(16):4220-36 e13.
  5. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585-94.
38.Nemat A, Asady A. The Third Wave of the COVID-19 in Afghanistan: An Update on Challenges and Recommendations. J Multidiscip Health. 2021;14:2043-2045.

39.Soriano V, de Mendoza C, Gómez-Gallego F, Corral O, Barreiro P. Third wave of COVID-19 in Madrid, Spain. Int J Infect Dis. 2021;107:212-214.

  1. Soriano V, Ganado-Pinilla P, Sanchez-Santos M, Gómez-Gallego F, Barreiro P, de Mendoza C, Corral O. Main differences between the first and second waves of COVID-19 in Madrid, Spain. Int J Infect Dis. 2021;105:374-376.
41.Raturi M, Kusum A. The blood supply management amid the COVID-19 outbreak. Transfus Clin Biol. 2020;27(3):147–151.

42.Riley W, Love K, McCullough J. Public policy impact of the COVID-19 pandemic on blood supply in the United States. Am J Public Health. 2021;111(5):860–866. 

  1. Sah R, Rodriguez-Morales AJ, Fathah Z, Shrestha S, Mehta R, Khatiwada AP, et al. Blood scarcity at the blood banks during COVID-19 pandemic and strategies to promote blood donations: current knowledge and futuristic vision.Egypt J Basic Appl Sci. 2021;8(1):261-8.
  2. Leung JNS, Lee CK. Impact of the COVID-19 – a regional blood centre’s perspective. ISBT Sci Ser. 2020;15(4):362–364.
45.Wang Y, Han W, Pan L, et al. Impact of COVID-19 on blood centres in Zhejiang province China. Vox Sang. 2020;115(6):502–506.

46.Haw J, Holloway K, Masser BM, et al. Blood donation and the global COVID-19 pandemic: areas for social science research. Vox Sang. 2021;116(4):363–365.

  1. Sachdev S, Kishore K, Singh L, et al. Exploration of COVID-19 related fears deterring from blood donation in India. ISBT Sci Ser. 2021;16 (2):147–157.
  2. Gammon RR, Prichard AB, Gannett MS, et al. The effect of COVID-19 on blood donation habits. Transfusion. 2021;61(4):1134–1140.
  3. Kumar S, Azim D, Nasim S, et al. Dwindling blood reserves: an ominous downside of COVID-19 pandemic. Transfus Apher Sci. 2020;59(5):102818.
  4. Nieto-Calvache AJ, Quintero-Santacruz M, Macia-Mejía C, et al. Dangerous shortage of blood banks as an indirect effect of SARS-CoV-2: an obstetrics perspective. Int J Gynaecol Obstet. 2020;151(3):424–430.
  5. Al-Riyami AZ, Abdella YE, Badawi MA, et al. The impact of COVID-19 pandemic on blood supplies and transfusion services in Eastern Mediterranean region. Transfus Clin Biol. 2021;28(1):16–24.
  6. Stanworth SJ, New HV, Apelseth TO, et al. Effects of the COVID-19 pandemic on supply and use of blood for transfusion. Lancet Haematol. 2020;7(10):e756–e764.
  7. WHO .WHO COVID-19 Dashboard - Up to date data on pandemic 2021. Availablefrom: https://covid19.who.int/?gclid=CjwKCAiApNSABhAlEiwANuR9YM0k0JigJ56NivXbxLo_GNuUC2W0j79EBV9ZLho5WBFDR7AO8Bt2ihoCqfoQAvD_BwE.
  8. Blasi F, Gramegna A, Sotgiu G, Saderi L, Voza A, Aliberti S, Amati F. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respir Med. 2021;180:106355.
  9. Dhama K, Sharun K, Tiwari R, Dhawan M, Emran TB, Rabaan AA, et al. COVID-19 vaccine hesitancy - reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vaccin Immunother. 2021;17(10):3495-9..
  10. Farooqi T, Malik JA, Mulla AH, Al Hagbani T, Almansour K, Ubaid MA, et al. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies. J Infect Public Health. 2021;14(10):1299-312.
  11. Lai CC, Chen IT, Chao CM, Lee PI, Ko WC, Hsueh PR. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines. 2021;20(8):1013-1025.
  12. Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules. 2021;11(7):993.
  13. Sharun K, Tiwari R, Dhama K, Emran TB, Rabaan AA, Al Mutair A. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. Hum Vaccin Immunother. 2021;23:1-4.
60.Schlagenhauf P, Patel D, Rodriguez-Morales AJ, Gautret P, Grobusch MP, Leder K. Variants, vaccines and vaccination passports: Challenges and chances for travel medicine in 2021. Travel Med Infect Dis. 2021; 40:101996.

  1. Sharun K, Dhama K. COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing Pandemic. Arch Med Res. 2021;52(7):761-3.
  2. Sharma N, Vyas S, Mohapatra A, Khanduri R, Roy P, Kumar R. Combating COVID-19 pandemic in India: Demystifying the concept of herd immunity. J Family Med Prim Care. 2021;10(4):1515-1519.
  3. Snehota M, Vlckova J, Cizkova K, Vachutka J, Kolarova H, Klaskova E, Kollarova H. Acceptance of a vaccine against COVID-19 - a systematic review of surveys conducted worldwide. Bratisl Lek Listy. 2021;122(8):538-547.
  4. Tareq AM, Emran TB, Dhama K, Dhawan M, Tallei TE. Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic. Hum Vaccin Immunother. 2021;17(11):4126–7.
  5. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, Jit M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023-1034.
  6. Yan ZP, Yang M, Lai CL. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals (Basel). 2021;14(5):406.
  7. Dhama K, Patel SK, Sharun K, Pathak M, Tiwari R, Yatoo MI, et al. SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel Med Infect Dis. 2020;37:101830.
  8. Malik YS, Sircar S, Bhat S, Sharun K, Dhama K, Dadar M, Tiwari R, Chaicumpa W. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40(1):68-76.
69.Tiwari R, Dhama K, Sharun K, Iqbal Yatoo M, Malik YS, Singh R, Michalak I, Sah R, Bonilla-Aldana DK, Rodriguez-Morales AJ. COVID-19: animals, veterinary and zoonotic links. Vet Q 2020;40:169–182.

  1. Banerjee A, Mossman K, Baker ML. Zooanthroponotic potential of SARS-CoV-2 and implications of reintroduction into human populations. Cell Host Microbe 2021;29:160– 164.
  2. Chavda VP, Feehan J, Apostolopoulos V. A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals. Vaccines (Basel). 2021;9(6):631.
  3. Karikalan M, Chander V, Mahajan S, Deol P, Agrawal RK, Nandi S, et al. Natural infection of Delta mutant of SARS-CoV-2 in Asiatic lions of India. Transbound Emerg Dis. 2021.
  4. Korath ADJ, Janda J, Untersmayr E, Sokolowska M, Feleszko W, Agache I, Adel Seida A, Hartmann K, Jensen-Jarolim E, Pali-Schöll I. One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-Cov-2. Allergy Eur J Allergy Clin Immunol 2021;2021:1-17.
  5. Sharun K, Dhama K, Pawde AM, Gortazar C, Tiwari R, Bonilla-Aldana DK, et al. SARS-CoV-2 in animals: potential for unknown reservoir hosts and public health implications. Vet Q. 2021;41(1):181-201.
  6. Tass. Russia registers world's first anti-coronavirus vaccine for animals [updated March 31, 2021. Available from: https://tass.com/world/1272331.
76. Vandeputte J, Van Damme P, Neyts J, Audonnet JC, Baay M, Neels P. Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development? Biologicals. 2021;73:1-7.

آمار
تعداد مشاهده مقاله: 2,549
تعداد دریافت فایل اصل مقاله: 3,349


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب